Assistance in Neurosurgery (ExtempoRMN) (ExtempoRMN)
Assistance in Neurosurgery by Extemporaneous Analysis of Magnetic Resonance of the Metabolic Content in Excised Tissues (ExtempoRMN)
The main ambition of this project is to develop, and provide the medical community, an innovative method to analyze extemporaneously, during a neurosurgery operation, excised tissues. This method is based on the analysis of the metabolic profile of excised tissues by the technique of High-Resolution Magic-Angle Spinning (HR-MAS) Nuclear Magnetic Resonance (NMR) spectroscopy. Indeed HRMAS NMR method can provide in a sufficiently short time lapse (currently about 30 minutes but within our project a time lapse of 15 min or even less is ultimately intended), medical information that can complement those obtained by classic histological examination.
Primary purpose:
The main objective of this study is to determine the sensitivity of HRMAS NMR spectroscopy in detecting residual tumor infiltration at the brain resection cavity. The investigators aim to determine the relevance of the metabolic analysis compared to histological analysis during a neurosurgery operation. This involves analyzing excised tissue samples, obtained from the operating rooms of Strasbourg University Hospitals, and Colmar Hospital Center, with no return to neurosurgeon for surgery.
Secondary purposes:
The secondary objectives of the protocol are to investigate the metabolome of different types of brain tumors, in order to find prognostic and diagnostic markers. It consists in detecting metabolomic factors of bad prognosis, and potential marker of good prognosis such as the IDH mutation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Izzie Jacques NAMER, MD
- Phone Number: 33.3.88.12.75.50
- Email: Izzie.Jacques.NAMER@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France
- Service de Biophysique et de Médecine Nucléaire, Hôpital de Hautepierre
-
Strasbourg, France
- Service de Neurochirurgie
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Male or female
- Age 18 years of age or older at the time of surgery
- Primary brain tumors (gliomas mainly) or epilepsy, for which neurosurgical intervention is programmed
- In the case of brain tumors: primary-lesions or transformation of low-grade gliomas into high-grade gliomas not treated with radiotherapy
- Affiliated with a social security
- Having signed the informed consent
- Having been informed of the results of the medical examination prior
Exclusion criteria:
- Relapse of tumors previously treated with radiotherapy or chemotherapy
- Subject under treatment (radiotherapy or chemotherapy) prior to surgery
- Metastatic lesions (location of the primary lesion outside the central nervous system)
- Inability to give to the subject or his/her family enlightened information (subject in emergency situation, difficulties of understanding...)
- Subject under judicial protection
- Subject under guardianship or curatorship
- Patients' Refusal
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percentage of the cases for which, the HRMAS NMR spectroscopy results of the excised tissues are consistent with quantitative histological analysis of the same excised tissues.
Time Frame: 3 years from the beginning of the study
|
To validate the primary endpoint of this study, statistical analysis should confirm this consistency in at least 95% of the cases.
|
3 years from the beginning of the study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Izzie Jacques Namer, MD, Hopitaux Universitaires de Strasbourg
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ExtempoRMN - RNI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
NCT07506239RecruitingPediatric Cancer | Low-grade Glioma | Low Grade Glioma of Brain | Recurrent Low Grade Glioma
-
NCT06964737RecruitingWHO Grade 3 Glioma | Recurrent Malignant Glioma | WHO Grade 2 Glioma | Recurrent WHO Grade 3 Glioma | Recurrent WHO Grade 4 Glioma | WHO Grade 4 Glioma
-
NCT05555550RecruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma Intracranial
-
NCT02208362Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III Glioma
-
NCT05553041RecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma Intracranial
-
NCT02525692TerminatedGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia Glioma
-
NCT03389230Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory Glioma
-
NCT03749187Active, not recruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma
-
NCT07389278Not yet recruitingGlioblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | High-grade Glioma | High-Grade Glioma (WHO III-IV) | Diffuse Hemispheric Glioma, H3G34 Mutant
-
NCT03952598SuspendedGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade Glioma
Clinical Trials on High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy
-
NCT06452173Enrolling by invitation
-
NCT07366619RecruitingAnterior Cruciate Ligament Injuries | Meniscus Tear
-
NCT05812040RecruitingBreast Neoplasms | Nipple Discharge
-
NCT05920616CompletedCOVID-19 | COVID Long-Haul
-
NCT03031275CompletedPneumonia | Sepsis | Critical Illness | Cognitive Impairment | Acute Respiratory Distress Syndrome | Extracorporeal Circulation; Complications | Long Term Adverse Effects
-
NCT02914288UnknownCerebral Arterial Diseases | Intimal Dissection | Dissecting Aneurysm of Cerebral Artery
-
NCT03980535CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
-
NCT03303846Active, not recruiting
-
NCT06842303Recruiting